Latest Intl Stem Cell Corp (ISCO) Headlines O
Post# of 124
Posted On: 03/10/2014 7:14:12 AM
Latest Intl Stem Cell Corp (ISCO) Headlines
Odemwingie Pleased With Stoke Debut
All Africa Global Media - Tue Feb 04, 4:56AM CST
Out of favour Super Eagles forward, Osaze Peter Odemwingie has spoken of his delight following his Barclays English Premier League debut for Stoke City last weekend. Odemwingie completed an 18-month move to the Britannia Stadium on January 28 and was immediately thrown into the deep end by the Stoke Manager, Mark Hughes, against Manchester United on Saturday.
International Stem Cell Corporation Advances Parkinson's Disease Program Towards IND Stage
Marketwire - Mon Sep 09, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies, announced today further progress in its Parkinson's disease program with a recently held key opinion leader meeting facilitated by the study's principal investigator, Dr. Mark Stacy of Duke Medicine.
International Stem Cell Corporation to Present at Rodman & Renshaw 15th Annual Global Investment Conference September 8th to 10th
Marketwire - Wed Aug 28, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that it will participate in Rodman & Renshaw's 15th Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
International Stem Cell Corporation Enters Into Clinical Research Agreement for Parkinson's Disease Program
Marketwire - Wed Aug 21, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's innovative neural stem cell product.
International Stem Cell Corporation Announces Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced financial results for the three and six months ended June 30, 2013.
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation
Marketwire - Tue Aug 06, 7:30AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on International Stem Cell Corporation (OTCQB: ISCO). The full 72-page report is available on Crystal Research Associates' website at www.crystalra.com.
International Stem Cell Corporation to Host Second Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Friday, August 9, 2013
Marketwire - Thu Aug 01, 4:00PM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Friday, August 9, 2013 to discuss its financial results for the three and six months ended June 30, 2013.
International Stem Cell Corporation prices public offering at USD0.15 per unit
M2 - Mon Jul 22, 6:22AM CDT
Biotechnology company International Stem Cell Corporation (OTCQB:ISCO) revealed on Friday that it has priced its public offering of 20,000,000 units at a price of USD0.15 per unit.
International Stem Cell Corporation Announces Pricing of Public Offering
Marketwire - Fri Jul 19, 7:24AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies, announced today the pricing of a public offering of 20,000,000 units, each unit consisting of one share of our common stock and one Series A Warrant to purchase one share of our common stock at an exercise price of $0.15 per share. The units are being offered at a price of $0.15 per unit. We are also offering up to 20,000,000 Series B Warrants, each to purchase one unit. Purchasers will receive one Series B Warrant for each unit purchased. Each Series A Warrant will be immediately exercisable at an initial exercise price of $0.15 per share. The Series A Warrants will expire on the fifth anniversary of the initial date of issuance
International Stem Cell Corporation to Present Data From Its Parkinson's Disease Program at Society for Neuroscience Annual Meeting
Marketwire - Thu Jun 27, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies, announced today that it will present preliminary data from its IND-enabling study in Parkinson's disease at the Society for Neuroscience annual meeting in San Diego, CA on November 10th 2013.
Lifeline Skin Care Expands Asian Distribution
Marketwire - Tue Jun 11, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies, biomedical and skin care products, announced today that Lifeline Skin Care, its operating subsidiary, has signed distribution agreements to sell its breakthrough stem cell skin care products in both Thailand and Viet Nam. Lifeline products will be launched in both countries this summer. Complementing Lifeline's current distribution relationship in China, these two new agreements demonstrate Lifeline's commitment to capitalize on the enormous opportunities in the Asian market. Throughout Asia, but particularly in Viet Nam, Thailand, Korea, Singapore and China, stem cells are heralded as the most important medical technology of the 21st century. Bringing that technology to cosmetic products, particularly for anti-aging, is a significant opportunity for Lifeline Skin Care (www.lifelineskincare.com).
International Stem Cell Corporation Initiates IND-Enabling Study in Parkinson's Disease Program
Marketwire - Thu May 30, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies, announced today the initiation of its IND-enabling pharmacology and toxicology non-human primate studies, under the direction of Yale School of Medicine Professor D. Eugene Redmond Jr. MD, the internationally recognized neurosurgeon and a leader in the use of stem cells for the treatment of Parkinson's disease.
International Stem Cell Corporation to Present at Two Upcoming Investor Conferences
Marketwire - Wed May 15, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies, today announced that it will be presenting at two investor conferences in May. Dr. Simon Craw, Executive Vice President, will present at the B. Riley & Co. 14th Annual Investor Conference in Santa Monica, CA Monday May 20, 2013 and the Marcum LLP 2nd Annual MicroCap Conference in New York City, New York on Thursday, May 30, 2013.
International Stem Cell Corporation Announces First Quarter 2013 Financial Results and Provides Business Update
Marketwire - Tue May 14, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies, today announced financial results for the three months ended March 31, 2013.
International Stem Cell Corporation to Host First Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Tuesday, May 14, 2013
Marketwire - Thu May 09, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced today that it will host a conference call on Tuesday, May 14, 2013 to discuss its financial results for the three months ended March 31, 2013.
International Stem Cell Corporation to Present at American Society of Gene and Cell Therapy 16th Annual Meeting
Marketwire - Wed May 01, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced that Dr. Ruslan Semechkin, VP of Research and Development, will present additional data from the primate study of the use of neuronal cells for the treatment of Parkinson's disease at the 16th Annual Meeting of American Society of Gene and Cell Therapy, May 15-18, 2013 at the Salt Palace Convention Center in Salt Lake City, UT.
International Stem Cell Corporation Announces Fourth Quarter 2012 Financial Results and Provides Business Update
Marketwire - Wed Mar 27, 7:02AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and biomedical products, today announced financial results for the three and twelve months ended December 31, 2012.
International Stem Cell Corporation to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and Provide Business Update
Marketwire - Tue Mar 26, 7:02AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company, today announced the management will host a conference call on Thursday, March 28, 2013 to provide a business update and discuss its financial results for the year ended December 31, 2012.
International Stem Cell Corp. to Host Conference Call on Friday, March 22 to Discuss Positive Study Data of Parkinson's Disease
Marketwire - Thu Mar 21, 6:01AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company, today announced that the Company will host a conference call on Friday, March 22, 2013 to discuss results of its Parkinson's Disease study that it presented at the American Academy of Neurology 65th Annual Meeting (AAN) on March 20, 2013. Dr. Ruslan Semechkin, Vice President of Research and Development for ISCO and Dr. Simon Craw, Executive Vice President will host the call.
International Stem Cell Corporation Announces Positive Stem Cell Data in Parkinson's Disease
Marketwire - Wed Mar 20, 7:00AM CDT
International Stem Cell Corporation (ISCC) (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells today announced positive results demonstrating the safety and efficacy of stem cell engraftment in a primate model of Parkinson's disease. The results were presented during the American Academy of Neurology (AAN) 65th Annual Meeting, Scientific Platform Session: Parkinson's Disease Therapeutics on Wednesday, March 20, 2013 in San Diego.
Odemwingie Pleased With Stoke Debut
All Africa Global Media - Tue Feb 04, 4:56AM CST
Out of favour Super Eagles forward, Osaze Peter Odemwingie has spoken of his delight following his Barclays English Premier League debut for Stoke City last weekend. Odemwingie completed an 18-month move to the Britannia Stadium on January 28 and was immediately thrown into the deep end by the Stoke Manager, Mark Hughes, against Manchester United on Saturday.
International Stem Cell Corporation Advances Parkinson's Disease Program Towards IND Stage
Marketwire - Mon Sep 09, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies, announced today further progress in its Parkinson's disease program with a recently held key opinion leader meeting facilitated by the study's principal investigator, Dr. Mark Stacy of Duke Medicine.
International Stem Cell Corporation to Present at Rodman & Renshaw 15th Annual Global Investment Conference September 8th to 10th
Marketwire - Wed Aug 28, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that it will participate in Rodman & Renshaw's 15th Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
International Stem Cell Corporation Enters Into Clinical Research Agreement for Parkinson's Disease Program
Marketwire - Wed Aug 21, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's innovative neural stem cell product.
International Stem Cell Corporation Announces Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced financial results for the three and six months ended June 30, 2013.
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation
Marketwire - Tue Aug 06, 7:30AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on International Stem Cell Corporation (OTCQB: ISCO). The full 72-page report is available on Crystal Research Associates' website at www.crystalra.com.
International Stem Cell Corporation to Host Second Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Friday, August 9, 2013
Marketwire - Thu Aug 01, 4:00PM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Friday, August 9, 2013 to discuss its financial results for the three and six months ended June 30, 2013.
International Stem Cell Corporation prices public offering at USD0.15 per unit
M2 - Mon Jul 22, 6:22AM CDT
Biotechnology company International Stem Cell Corporation (OTCQB:ISCO) revealed on Friday that it has priced its public offering of 20,000,000 units at a price of USD0.15 per unit.
International Stem Cell Corporation Announces Pricing of Public Offering
Marketwire - Fri Jul 19, 7:24AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies, announced today the pricing of a public offering of 20,000,000 units, each unit consisting of one share of our common stock and one Series A Warrant to purchase one share of our common stock at an exercise price of $0.15 per share. The units are being offered at a price of $0.15 per unit. We are also offering up to 20,000,000 Series B Warrants, each to purchase one unit. Purchasers will receive one Series B Warrant for each unit purchased. Each Series A Warrant will be immediately exercisable at an initial exercise price of $0.15 per share. The Series A Warrants will expire on the fifth anniversary of the initial date of issuance
International Stem Cell Corporation to Present Data From Its Parkinson's Disease Program at Society for Neuroscience Annual Meeting
Marketwire - Thu Jun 27, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies, announced today that it will present preliminary data from its IND-enabling study in Parkinson's disease at the Society for Neuroscience annual meeting in San Diego, CA on November 10th 2013.
Lifeline Skin Care Expands Asian Distribution
Marketwire - Tue Jun 11, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies, biomedical and skin care products, announced today that Lifeline Skin Care, its operating subsidiary, has signed distribution agreements to sell its breakthrough stem cell skin care products in both Thailand and Viet Nam. Lifeline products will be launched in both countries this summer. Complementing Lifeline's current distribution relationship in China, these two new agreements demonstrate Lifeline's commitment to capitalize on the enormous opportunities in the Asian market. Throughout Asia, but particularly in Viet Nam, Thailand, Korea, Singapore and China, stem cells are heralded as the most important medical technology of the 21st century. Bringing that technology to cosmetic products, particularly for anti-aging, is a significant opportunity for Lifeline Skin Care (www.lifelineskincare.com).
International Stem Cell Corporation Initiates IND-Enabling Study in Parkinson's Disease Program
Marketwire - Thu May 30, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies, announced today the initiation of its IND-enabling pharmacology and toxicology non-human primate studies, under the direction of Yale School of Medicine Professor D. Eugene Redmond Jr. MD, the internationally recognized neurosurgeon and a leader in the use of stem cells for the treatment of Parkinson's disease.
International Stem Cell Corporation to Present at Two Upcoming Investor Conferences
Marketwire - Wed May 15, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies, today announced that it will be presenting at two investor conferences in May. Dr. Simon Craw, Executive Vice President, will present at the B. Riley & Co. 14th Annual Investor Conference in Santa Monica, CA Monday May 20, 2013 and the Marcum LLP 2nd Annual MicroCap Conference in New York City, New York on Thursday, May 30, 2013.
International Stem Cell Corporation Announces First Quarter 2013 Financial Results and Provides Business Update
Marketwire - Tue May 14, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies, today announced financial results for the three months ended March 31, 2013.
International Stem Cell Corporation to Host First Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Tuesday, May 14, 2013
Marketwire - Thu May 09, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced today that it will host a conference call on Tuesday, May 14, 2013 to discuss its financial results for the three months ended March 31, 2013.
International Stem Cell Corporation to Present at American Society of Gene and Cell Therapy 16th Annual Meeting
Marketwire - Wed May 01, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced that Dr. Ruslan Semechkin, VP of Research and Development, will present additional data from the primate study of the use of neuronal cells for the treatment of Parkinson's disease at the 16th Annual Meeting of American Society of Gene and Cell Therapy, May 15-18, 2013 at the Salt Palace Convention Center in Salt Lake City, UT.
International Stem Cell Corporation Announces Fourth Quarter 2012 Financial Results and Provides Business Update
Marketwire - Wed Mar 27, 7:02AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and biomedical products, today announced financial results for the three and twelve months ended December 31, 2012.
International Stem Cell Corporation to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and Provide Business Update
Marketwire - Tue Mar 26, 7:02AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company, today announced the management will host a conference call on Thursday, March 28, 2013 to provide a business update and discuss its financial results for the year ended December 31, 2012.
International Stem Cell Corp. to Host Conference Call on Friday, March 22 to Discuss Positive Study Data of Parkinson's Disease
Marketwire - Thu Mar 21, 6:01AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company, today announced that the Company will host a conference call on Friday, March 22, 2013 to discuss results of its Parkinson's Disease study that it presented at the American Academy of Neurology 65th Annual Meeting (AAN) on March 20, 2013. Dr. Ruslan Semechkin, Vice President of Research and Development for ISCO and Dr. Simon Craw, Executive Vice President will host the call.
International Stem Cell Corporation Announces Positive Stem Cell Data in Parkinson's Disease
Marketwire - Wed Mar 20, 7:00AM CDT
International Stem Cell Corporation (ISCC) (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells today announced positive results demonstrating the safety and efficacy of stem cell engraftment in a primate model of Parkinson's disease. The results were presented during the American Academy of Neurology (AAN) 65th Annual Meeting, Scientific Platform Session: Parkinson's Disease Therapeutics on Wednesday, March 20, 2013 in San Diego.
(0)
(0)Intl Stem Cell Corp (ISCO) Stock Research Links
Scroll down for more posts ▼